Edited by Peter Hillerberg1 min readStories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
MRVL drew the sharpest target price lift of the day. The consensus target rose to $311.97, up from $308.60, as analysts continued to build conviction around the chipmaker's AI networking exposure. Sixteen analysts hold buy ratings on the stock, with no sells on record.
Pharma dominated the upgrade list elsewhere. LLY saw its average target nudge up to $1,329, reflecting 25 buy ratings and just one sell. REGN climbed to an $856 consensus target. BMY also moved higher. The AbbVie alternative data from ORTEX drug trial data shows trial completion slippage running 0.6 standard deviations below its own history, a small positive signal for the class.
MSFT received a target increase to $587.63. All 55 covering analysts rate it a buy, making it the most uniformly bullish large-cap name in the data.
On the downside, DAL saw its target trim to $101.60. All 24 analysts rate it a buy, but the cut reflects caution around near-term margins. T fell to a $28.46 consensus target, with sells rising. DIS also saw a small target reduction, with 29 buy ratings but two sells on the board.
FCX bucked the energy sector trend, lifting its target to $75.50. DVN and COP saw modest moves in opposite directions.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
